// App-Quantinova.ai

PB0167 : Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1

Researchers

Presenter

  • T. Petzold

Principal Investigators

  • L. Dannenberg

  • P. Mourikis

  • C. Helten

  • R. M'Pembele

  • K. Trojovsky

  • Z. Zhang

  • R. Regenauer

  • J. Pircher

  • A. Ehrlich

  • E. Lsebrink

  • L. Nicolai

  • T. Stocker

  • R. Brandl

  • F. Rschenthaler

  • J. Strecker

  • T. Hohlfeld

  • M. Kelm

  • A. Polzin

Medical Centers

  • TU München,München,Germany

  • University Hospital, Duesseldorf, Germany

  • St. Mary's Square Institute for Vascular Surgery and Phlebology, München, Germany

  • German Heart center, Institute for Laboratory Medicine, Technical University Munich, München, Germany

  • Heinrich Heine University Duesseldorf, Duesseldorf, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

Disease

  • Arrhythmia

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved